The Role of Infection in Atherosclerosis and Coronary Artery Disease: A New Therapeutic Target

Heart Disease

Volumn 1, Issue 4, 1999, Pages 233-240

  Ismail, Anjum ^a,c   Khosravi, Hamed ^b   Olson, Harold ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b St Barnabas Medical Center   (United States)

^c UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; MICROBIOLOGY; PATHOPHYSIOLOGY; REVIEW;

CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; INFLAMMATION;

EID: 0033188294     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (124)

1. Davies MJ, Woolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 1988;60: 459-454.
2. Lerman A, Edwards BS, Hallet JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
3. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary artery disease: the Framingham study. Am J Med 1977;62:707-714.
4. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148: 36-69.
5. Romm PA, Green CE, Regan K, Rackley CE. Relation of serum lipoprotein cholestrol levels to the presence and severity of angiographic coronary artery disease. Am J Cardiol 1991;67:479-483.
6. Manninen V, Tenkanen L, Koskinn P, Huttunen JK, Manttari M, Heinonen OP, Frick MI. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary artery disease in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.
7. Assmann G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-737.
8. Criqui MH, Heiss G, Cohn R, Cown LD, Suchindran CM, Bandiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-1225.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP). JAMA 1993;216:3015-3023.
10. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344: 793-795.
11. Andrews HE, Bruckdorfer KR, Dunn RC, Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature 1987;327: 237-239.
12. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high density lipoprotein on acetylcholine induced coronary vasoreactivity. Am J Cardiol 1991;68:1425-1430.
13. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, et al. Nitric oxide activity in the human coronary circulation: Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995;95:1747-1755.
14. Wenzel RR, Duthiers N, Noll G, Bucher J, Kaufmann U, Luscher TF. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation 1996;94:316-322.
15. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
16. Berliner JA, Navab M, Fogelman AM, Frank JS,Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms, oxidation, inflammation and genetics. Circulation 1995;91:2488-2496.
17. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, et al. Evidence for the presence of oxidized modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-1095.
18. Holvoet P, Perez G, Zhao Z, Browers E, Bernar H, Collen D. Malondialdehyde-modified LDL in patients with atherosclerotic disease. J Clin Invest 1995;95:2611-2619.
19. Libby P. Molecular bases of the acute coronary syndrome. Circulation 1995; 91:2844-2850.
20. Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, et al. Autoantibody titers to oxidized LDL in patients with coronary atherosclerosis. Am Heart J 1996;131:663-667.
21. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295:369-377, 420-425.
22. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
23. Sohal RS, Burch GE, Chu KC, Leiderman E, Colcolough HL. Ultrastructural changes in cardiac capillaries of Coxsackie virus B4 infected mice. Lab Invest 1968;19:399-405.
24. Burch GE, Shewey LL. Viral coronary arteritis and myocardial infarction. Am Heart J 1976;92:11-14.
25. Nicholls AC, Thomas M. Coxsackie virus infection in acute myocardial infarction. Lancet 1977;1:883-884.
26. Woods JD, Nimmo MJ, Mackay-Scollay EM. Acute transmural myocardial infarction associated with active coxsackie virus B infection. Am Heart J 1975; 89:283-287.
27. Wood SF, Rogen AS, Bell EJ. Role of Coxsackie B viruses in myocardial infarction. Br Heart J 1978;40:523-525.
28. O'Neill D, McArthur JD, Kennedy JA. Coxsackie B virus infection in coronary care unit patients. J Clin Pathol 1983;36:658-661.
29. Moss NS, Benditt EP. The ultrastructure of spontaneous and experimentally induced arterial lesion. II. The spontaneous plaque in the chicken. Lab Invest 1970;23:231-245.
30. Benditt EP, Gown AM. Atheroma: the artery wall and the environment. Int Rev Exp Pathol 1980;21:55-118.
31. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human athero sclerotic plaques. Proc Natl Acad Sci U S A 1973;70:1753-1756.
32. Steinberg BM, DiLorenzo TP. A possible role of human papillomaviruses in head and neck cancer. Cancer Metastasis Rev 1996;15:91-112.
33. Farrell PJ, Cludts I, Stuhler A, Epstein-Barr virus genes and cancer cells. Biomed Pharmacother 1997;51:258-267.
34. Vasssilandonopoulou G, Panotopoulou E, Fotiou S, Tserkezoglou A. Human papilloma-viruses in cervical cancer. I. HPV-16 and 18 predominate in the Greek population. Anticancer Res 1997;17:117-120.
35. Fabricant CG, Fabricant J, Minick CR. Herpes virus induced atherosclerosis in chickens. Fed Proc 1983;42:2476-2479.
36. Fabricant CG, Hajjar DP, Minick CR. Herpes virus infection enhances cholesterol and cholesterol ester accumulation in cultured arterial smooth muscle cells. Am J Pathol 1981;105:176-184.
37. Hajjar DP, Fabricant CG, Minick CR. Virus induced atherosclerosis. Herpes virus infection alters cholesterol metabolism and accumulation. Am J Pathol 1986;122:62-70.
38. Fabricant CG, Fabricant J, Litrenta MM. Virus-induced atherosclerosis. J Exp Med 1978;148:335-340.
39. Minick CR, Fabricant CG, Fabricant J. Atherosclerosis induced by infection with a herpes virus. Am J Pathol 1979;96:673-706.
40. Benditt HP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A 1983;80:6386-6389.
41. Melnick JL, Dreesman GR, McCollum CH. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983;2:644-647.
42. Yamashiroya HM, Ghosh L, Yang R. Herpes virdae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988;130:71-79.
43. Gyorkey F, Melnick JL, Guinn GA. Herpes viridae in the endothelial and smooth muscle cells of the proximal aorta of atherosclerosis patients. Exp Mol Pathol 1984;40:328-339.
44. Petrie BL, Melnick JL, Adam E. Nucleic acid sequence of cytomegalovirus in cells cultured from human arterial tissue. J Infect Dis 1987;155:158-159.
45. Hendrix MGR, Salimens MMM, Vauboven CPA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990;136:23-28.
46. Speir E, Modali R, Huang E-S. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-394.
47. Normann SJ, Salmon DR, Leelachaikul P. Acute vascular rejection of the coronary arteries in human heart transplantation: pathology and correlations with immunosuppression and cytomegalovirus infection. J Heart Lung Transplant 1991;10:674-687.
48. Ventura HO, Smart HW, Stapleton DD, Toups T, Price HL. Cardiac allograft vasculopathy: current concepts. J La State Med Soc 1993;145:195-198.
49. Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: current concepts. Am Heart J 1995;129:791-799.
50. Mehra MR, Ventura HO, Smart FW, Stapleton DD, Collins TJ. New developments in the diagnosis and management of cardiac allograft vasculopathy. Tex Heart Inst J 1995;22:138-144.
51. Koskinen PK, Nieminen MS, Krogerus LA. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant 1993;12:724-729.
52. Koskinen PK, Nieminen MS, Krogerus LA. Cytomegalovirus infection accelerates cardiac allograft vasculopathy: correlation between angiographic and endomyocardial biopsy findings in heart transplant patients. Transplant Int 1993;6:341-347.
53. Normann SJ, Salmon DR, Leelachaikul P, Khan SR, Staples ED. Acute vascular rejection of the coronary arteries in human heart transplantation: pathology and correlations with immunosuppression and cytomegalovirus infection. J Heart Lung Transplant 1991;10:674-687.
54. Koskinen P, Lemstrom K, Mattila S, Hayry P, Nieminen MS. Cytomegalovirus infection associated accelerated heart allograft arteriosclerosis may impair the late function of the graft. Clin Transplant 1996;10:487-493.
55. Wu TC, Hruban RH, Ambinder RF, Pizzorno M, Cameron DE. Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. Am J Pathol 1992;140:739-747.
56. Koskinen P, Lemstrom K, Bruggeman C, Lautenschlager I, Hayry P. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall: a possible linkage with enhanced allograft arteriosclerosis. Am J Pathol 1994;144:41-50.
57. Lemstrom K, Koskinen P, Krogerus L, Daemen M, Bruggeman C. Cytomegalvirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 1995;92: 2594-2604.
58. Grayston JT, Campbell LA, Kuo CC. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-625.
59. Grayston JT, Kuo CC, Wang SP. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986;315:161-168.
60. Wang S-P, Grayston JT. Microimmunofluorescence serological studies with the TWAR organism. In, Oriel JD, Ridgway G, Schachter J, et al (eds.): Chlamydial Infections. Cambridge: Cambridge University Press, 1986;329-332.
61. Wang S-P, Grayston JT. Population prevalence antibody to Chlamydia pneumoniae, strain TWAR. In, Bowie WR, Caldwell HD, Jones RP, et al (eds.): Chlamydial Infections. Cambridge: Cambridge University Press, 1990;402-405.
62. Ekman MR, Leinonen M, Syrjala H, Linnanmaki E, Kujala P, Saikku P. Evaluation of serological methods in the diagnosis of Chlamydia pneumoniae pneumonia during an epidemic in Finland. Eur J Clin Microbiol Infect Dis 1993;12:756-760.
63. Ekman M-R, Grayston JT, Visakorpi R, Kleemola M, Kud CC, Saikku P. An epidemic of infections due to Chlamydia pneumoniae in military conscripts. Clin Infect Dis 1993;17:420-425.
64. Campbell LA, Perez-Melgosa M, Hamilton DJ, Kuo CC, Grayston JT. Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol 1992;30:434-439.
65. Gaydos CA, Quinn TC, Eiden JJ. Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene. J Clin Microbiol 1992;30:796-800.
66. Tong CYW, Sillis M. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993;45:313-317.
67. Gaydos CA, Roblin PM, Hammerschlag MR, Hyman CL, Eiden JJ, Schaeter J, et al. Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol 1994;32:903-905.
68. Chirgwin K, Roblin PM, Gelling M. Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis 1991;163:757-761.
69. Saikku P, Leinonen M, Mattila K. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-986.
70. Saikku P, Leinonen M, Tenkanen L. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in Helsinki Heart Study. Ann Intern Med 1992;116:273-278.
71. Thom Dh, Wang S, Grayston JT. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991;11:547-551.
72. Thom DH, Grayston JT, Siscovick DS. Association of prior infection with Chlamydia pneuomoniae and angiographically demonstrated coronary artery disease. JAMA 1992;268:68-72.
73. Syrjanen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischemic brain infarction in young and middle aged patients. Br Med 1988;296:1156-1160.
74. Grau AJ, Buggle F, Heindl S. Recent infection as a risk factor for cerebrovascular ischemia. Stroke 1995;26:373-379.
75. Grayston JT, Campbell LA. The rule of Chlamydia pneumoniae in atherosclerosis (editorial response). Clin Infect Dis 1999;28:993-994.
76. Davidson M, Kuo C-C, Middaugh JP, Campbell LA, Wang S-P, Newman WP III, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998;98:628-633.
77. Torgano G, Cosentini R, Mandelli C, Perondi R, Blasi F, Bertinieri G, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999;99:1555-1559.
78. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation 1999;99: 1540-1547.
79. Juvonen J, Juvonen T, Laurila A. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997;25:499-505.
80. Campbell LA, O'Brien ER, Cappuccio AL. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995;172: 585-588.
81. Weiss SM, Roblin PM, Gaydos CA. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996; 173:957-962.
82. Kuo CC, Grayston JT, Campell LA. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A 1995;92:6911-6914.
83. Muhlestein JB, Hammond EH, Carlquist JF. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardivascular disease. J Am Coll Cardiol 1996;27:1555-1561.
84. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996;125:979-982.
85. Wimmer MLJ, Sandmann-Strupp R, Saikku P. Association of Chlamydia infection with cerebrovascular disease. Stroke 1996;27:2207-2210.
86. Kuo CC, Coulson AS, Campbell LA. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 1997;26:29-31.
87. Shor A, Kuo CC, Pattom DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. South Afr Med J 1992;82: 158-161.
88. Kuo CC, Shor A, Campbell LA. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-849.
89. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96: 404-407.
90. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, Litvak R, Testa E, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-407.
91. Juvonen J, Laurila A, Juvonen T, Alakarppa H, Sureel HM, Lounatmaa K, et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1997;29:1054-1059.
92. Megraud F. Epidemiology of Helicobacter pylori infection. Gastroenterol Clin North Am 1993;22:73-88.
93. Mendall MA, Coggin PM, Molineuux N. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437-439.
94. Strachan DP, Mendall MA, Carrington D, Butland BK, Yarnell JWG, Sweetnam PM, Elwood PC. Relation of Helicobacter pylori infection to 13 year mortality and incident ischemic heart disease in the Caerphilly Prospective Heart Disease Study. Circulation 1998;98:1286-1290.
95. Sammalkorpi K, Valtonen V, Kerttula Y. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988;37:859-865.
96. Murray LJ, Bemford KB, O'Reilly DPJ. Helicobacter pylori infection: relation with cardiovascular risk factors, ischemic heart disease, and social class. Br Heart J 1995;74:497-501.
97. Niemela S, Karttunen T, Korhonen T. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations. Heart 1996;75:573-575.
98. Blasi F, Denti F, Erba M. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996;34:2766-2769.
99. Pasceri V, Cammarota G, Parti G, Cuoco L, Gastarrini A, Grillo RL, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998;97:1675-1679.
100. Hasdai D, Scheinowitz M, Leibovitz E, Sclarovsky S, Eldar M, Barak V. Increased serum concentration of interleukin-1 beta in patients with coronary artery disease. Heart 1996;76:24-28.
101. Bernard DR, Langlois MR, Delanghe JR, De Buyzere ML. Evolution of haptoglobin concentration in serum during the early phase of acute myocardial infarction. Eur J Clin Chem Clin Biochem 1997;35:85-88.
102. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB, and the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-466.
103. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: the Multiple Risk Factor Intervention Trail. Am J Epidemiol 1996;144:537-547.
104. Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996;27:1656-1661.
105. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424.
106. Pietila KO, Harmoinen AP, Jokiniity J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996;17:1345-1349.
107. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997;96:778-784.
108. Lilienfeld DE, Gunderson PD, Sprafka JM. Epidemiology of aortic aneurysms. I. Mortality trends in the United States. Arteriosclerosis 1987;7:637-643.
109. Fowkes FGC, MacIntyre CCA, Ruckley CV. Increasing incidence of aortic aneurysms in England and Wales. Br Med J 1989;298:33-35.
110. MacSweency STR, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg 1994;81:935-941.
111. Beckman EN. Plasma cell infiltrates in atherosclerotic abdominal aortic aneurysms. Am J Clin Pathol 1986;85:21-24.
112. Brophy CM, Reilly JM, Smith GJ. The role of inflammation in non specific abdominal aortic aneurysm disease. Ann Vasc Surg 1991;5:229-233.
113. Nery EB, Meiste F, Ellinger RF. Prevalence of medical problems in periodontal patients obtained from three different populations. J Clin Periodontol 1987; 58:564-568.
114. Umino M, Nagao M. Systemic diseases in elderly dental patients. Int Dent J 1993;43:213-218.
115. Mackenzie RS, Millard HD. Interrelated effects of diabetes, arteriosclerosis and calculus on alveolar bone loss. J Am Dent Assoc 1963;66:192-198.
116. Mattila KJ, Nieminen M, Valtonen V, Rosi VP, Kesaniemi YA, Syrjala SL, et al. Association between dental health and acute myocardial infarction. Br Med J 1989;298:779-782.
117. Mattila KJ, Valle MS, Nieminen MS, Valtonen VV, Hietaniemi KL. Dental infections and coronary atherosclerosis. Atherosclerosis 1993;103:205-211.
118. Syrjanen J, Peltola J, Valtonen V. Dental infections in association with cerebral infarction in young and middle-aged men. J Intern Med 1989;225:179-184.
119. Paunio K, Impivaara O, Tiesko J. Missing teeth and ischemic heart disease in men aged 45-64 years. Eur Heart J 1993;14(suppl K):54-56.
120. Loesche WJ. Periodontal disease as a risk factor for heart disease. Compendium Continuing Educ Dent 1994;15:976-991.
121. Beck J, Garcia R, Heiss G. Periodontal disease and cardiovascular disease. J Periodontol 1996;67:1123-1137.
122. Grau AJ, Buggle F, Ziegler C, Schwarz W, Meuser J, Tasman AJ, et al. Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke 1997;28:1724-1729.
123. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
124. Schussheim AE, Fuster V. Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes. Drugs 1999;57: 283-291.